The Zollinger-Ellison Syndrome. Its Place in the Pathophysiology of Gastric Acid Secretion and of its Hormonal Regulation

Perkier, C. V.

doi:10.1007/978-3-642-94912-8_3

Cited by 4 publications

(1 citation statement)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the past, gastric acid hypersecretion 138,151,175,207,209,336,502,504 now can be treated effectively medically in almost every patient with ZES 199,203,204,207,277,280,488 ; no patient died of its effects in the current study. Similar conclusions to control of gastric acid secretion exist for the control of the pituitary disease, or the control of the hyperparathyroidism and prevention of the resultant renal failure, which were important contributing factors in the deaths of these patients in the past 58,62,125,133,253,468,484 .…”

Section: Discussioncontrasting

confidence: 71%

Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome

et al. 2004

View full text Add to dashboard Cite

In patients with multiple endocrine neoplasia type 1 (MEN1), the most common functional pancreatic endocrine tumor (PET) syndrome is Zollinger-Ellison syndrome (ZES). ZES has been well studied in its sporadic form (that is, without MEN1); however, there are limited data on patients with MEN1 and ZES (MEN1/ZES), and the long-term natural history is largely unknown. To address this issue we report the results of a prospective long-term National Institutes of Health (NIH) study of 107 MEN1/ZES patients and compare our results with those of 1009 MEN1/ZES patients in 278 case reports and small series in the literature. Patients were clinically, radiologically, and biochemically evaluated yearly for all MEN1 manifestations (mean follow-up, 10 yr; range, 0.1-31 yr). Compared with patients from the literature, the NIH MEN1/ZES patients more frequently had pituitary (60%) and adrenal (45%) disease and carcinoid tumors (30%), but had equal frequency of hyperparathyroidism (94%), thyroid disease (6%), or lipomas (5%). Twenty-five percent of both the NIH and the literature patients lacked a family history of MEN1; ZES was the initial clinical manifestation of MEN1 in 40%. ZES onset preceded the diagnosis of hyperparathyroidism in 45%. However, ZES was rarely (8%) the only initial manifestation of MEN1 if careful testing was done. ZES occurred before age 40 years in 50%-60% of the current patients, in contrast to older studies. The diagnosis of ZES is delayed 3-5 years from its onset and is delayed as long as in sporadic ZES cases. Pituitary disease and carcinoid tumors (gastric > bronchial, thymic) are more frequent than generally reported, whereas a second functional PET is uncommon. In patients with MEN1/ZES without a family history of MEN1, the MEN1 manifestations are not as severe. This study shows that MEN1/ZES patients differ in many aspects from those commonly reported in older studies involving few MEN1/ZES patients. In this study we have identified a number of important clinical and laboratory features of MEN1/ZES that were not previously appreciated, which should contribute to earlier diagnosis and improve both short- and long-term management.

show abstract